MRNA Stock Analysis: Buy, Sell, or Hold?
MRNA - Moderna, Inc. Common Stock
$48.73
-0.84 (-1.68%)
▼
5d:
-4.98%
30d:
-9.04%
90d:
+56.17%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
MRNA is down 4.8% this week, but smart money is accumulating calls. Top strike: $50 2026-05-15 with 25,043 OI. Call ratio: 70% View Scanner →
Strength: 4.5/10
Get Alerted When MRNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MRNA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MRNA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MRNA is currently trading at $48.73, which is considered slightly low relative to its 30-day fair value range of $49.35 to $54.77.
Technical Outlook: Technically, MRNA is in a strong uptrend. The price is currently testing key support at $50.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $43.75. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MRNA is in a strong uptrend. The price is currently testing key support at $50.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $43.75. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$49.35 -
$54.77
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 11.7% above Wall St target ($43.75)
Fair Price Analysis
30-Day Fair Range
$49.35 -
$54.77
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$50.19
Resistance Level
$56.51
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.90
Wall Street Target
$43.75
(-11.7%)
Revenue Growth (YoY)
-29.8%
Earnings Growth (YoY)
-85.1%
Profit Margin
-145.2%
Share & Embed Analysis
Last updated: March 30, 2026 10:21 AM ET
Data refreshes hourly during market hours. Next update: 11:21 AM
Data refreshes hourly during market hours. Next update: 11:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRNA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Stephen Hoge
SELL
160009 shares
2026-02-23
Ro Khanna
BUY
2026-01-23
Noubar Afeyan
SELL
23853 shares
2025-12-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
Advanced MRNA Option Strategies
Professional options setups generated by AI based on today's MRNA price and gamma walls.
